Between the 21st and 29th January Tillotts Pharma UK were proud to be headline sponsors of two virtual events, BSG […]
Tillotts Pharma UK made the donation of £2320 to the UK’s leading charity for Crohn’s disease and ulcerative colitis, Crohn’s […]
Tillotts Pharma AG has a strong presence in Europe with affiliates and distributors in all major European markets. The UK business is the largest wholly owned affiliate of Switzerland based Tillotts Pharma AG, and part of the Japanese Zeria Group.
Tillotts Pharma UK Ltd was established in March 2010. Jeremy Thorpe (Managing Director) joined in July 2012, with a clear focus on optimising the portfolio of gastrointestinal (GI) health products. Tillotts Pharma UK is now a market leader.
Since its foundation, Tillotts has been committed to improving care for people with gastrointestinal (GI) diseases. We collaborate with healthcare professionals and GI-experts to develop and market medicines for the treatment of diseases of the digestive system.
Our specific focus on the digestive system means we have in-depth knowledge of the challenges that gastroenterologists and hepatologists face on a daily basis. It also helps us look for innovative ways to improve care and quality of life for the 5–6 million people who live with inflammatory bowel diseases worldwide.